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The interest of the pharmaceutical industry in lipid drug delivery systems due to their prolonged release profile,
biocompatibility, reduction of side effects, and so on is already known. However, conventional methods of
preparation of these structures for their use and production in the pharmaceutical industry are difficult since these
methods are usually multi-step and involve high amount of organic solvent. Furthermore, some processes need
extreme conditions, which can lead to an increase of heterogeneity of particle size and degradation of the drug.
An alternative for drug delivery system production is the utilization of supercritical fluid technique. Lipid particles
produced by supercritical fluid have shown different physicochemical properties in comparison to lipid particles
produced by classical methods. Such particles have shown more physical stability and narrower size distribution.
So, in this paper, a critical overview of supercritical fluid-based processes for the production of lipid micro- and
nanoparticles is given and the most important characteristics of each process are highlighted.
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Introduction
Nowadays, the utilization of supercritical fluid-based
technology is considered as a promising substitute to the
traditional methods of particle production since it is an
efficient and environment-friendly technique. Supercrit-
ical fluids are defined as substances for which both
temperature and pressure are above critical values. Be-
yond this point, the liquid and gas phases become indis-
tinguishable because the densities of the phases are
identical, and only a homogeneous medium exists [1].
Supercritical fluids have many industrial applications,
including chemical reactions, extraction of essential oils,
supercritical chromatography, manufacturing of semi-
conductors, micronization of pharmaceutical excipients,
production of drug delivery systems, and so on [2,3].
The most widely used supercritical fluid in drug delivery
applications is carbon dioxide (CO2) because of a low
critical temperature of 304 K and a moderate critical* Correspondence: islane@gmail.com
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reproduction in any medium, provided the origpressure of 7.3 MPa. It is nonflammable, nontoxic, and
environment friendly; it is miscible with a variety of or-
ganic solvents and is readily recovered after processing.
It is also a small and linear molecule and thus diffuses
faster than conventional liquid solvents.
Supercritical carbon dioxide (scCO2) offers a wide
range of possible applications in the pharmaceutical field
[4], which allows the processing of bioactive compounds
under mild operation conditions avoiding their degrad-
ation [5]. The use of CO2 as solvent or raw material has
been investigated in academia and/or industry since
1950 and has intensified 30 years later with the imple-
mentation of large-scale plants using online systems [6].
The approaches for processing bioactive compounds in-
clude mainly the particle size reduction of bulk products
to nanometer scale [7] and association of drug molecules
to particulate carriers [8].
CO2 molecule possesses no dipole moment, which
means that it is nonpolar and, when it is in supercritical
state, CO2 can be a good solvent to solubilize nonpolar
substances. However, CO2 possesses a quadrupole mo-
ment, which enables the dissolution of some polar and
slightly polar compounds at high pressures [9,10]. So,his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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and lipids, typical drug carriers. The solubilization of scCO2
promotes decrease in viscosity of the molten drug carrier,
making possible their bombing through the plant [11].
Other significant advantages of supercritical fluid pro-
cessing include its nonflammability, its relative low cost,
the possibility of its total recycling, the production of or-
ganic solvent-free particles, the achievement of particu-
late systems with a narrow particle size distribution, and
the its one-step operation. Furthermore, all processes
run into a closed system facilitating the establishment of
an ascetical production of sterile formulations [6,12,13].
Liposomes
Liposomes are colloidal associations of amphiphilic
lipids that organize themselves spontaneously in bi-
layer vesicles as a result of unfavorable interactions be-
tween phospholipids and water. As they have lipophilic
and hydrophilic portions, liposomes can entrap sub-
stances with varying lipophilicities in the phospholipid
bilayer, in the aqueous compartment, or at the bilayer
interface [14-16] which can modify physicochemical
properties and enhance the biological activity of the
compounds [17].
As liposomes are composed of phospholipids, they
have interesting physical and chemical properties, such
as osmotic activity, permeability of their membranes to
different solutes, and also the capacity of interacting
with membranes of different cell types [18]. They also
have the ability of minimizing side effects of drugs,
protecting them from degradation, specific targeting,
and biocompatibility [19].
Selecting the method of liposome production is related
to the materials or the lipid composition of the vesicles
that will be used. The starting point for all conventional
methods of liposome production is the dissolution of
phospholipids in an organic solvent, and the main differ-
ence between these methods is the way in which the
lipid membrane is dispersed in aqueous media [20-25].
These methods have some drawbacks in common, such
as the large number of steps needed to produce the vesi-
cles, the utilization of a large amount of organic solvent
in the beginning or during the process, the lack of diam-
eter size uniformity and, moreover, the low stability of
produced particles [26]. To overcome these drawbacks,
the utilization of supercritical fluid is an alternative to
produce these nanoparticles.
Liposome production by scCO2 processing
As aforementioned, supercritical fluid technology is an in-
teresting alternative for the production of safer and more
stable drug delivery particles. Indeed, the utilization of
supercritical fluid technology in the production of lipo-
somes entrapping pharmaceuticals and biopharmaceuticalsis a promising field under intense investigation. Table 1
summarizes different methods to produce liposomes using
supercritical fluids.Supercritical liposome method
Frederiksen et al. [27] created a laboratory method
aiming to produce liposomes encapsulating water-
soluble compounds utilizing scCO2 as an alternative to
utilizing large amounts of organic solvents. The appar-
atus developed for this method is depicted in Figure 1
and it is divided into two parts: a high-pressure and a
low-pressure system that possess a recycling loop each
and are connected by a capillary. The presence of this
capillary before the low-pressure system allows the
addition of the aqueous solution in the bulk of phospho-
lipid solution, which increases the encapsulation of
water-soluble compounds into liposomes. Briefly, phos-
pholipids and cholesterol were added into the high-
pressure system and dissolved in scCO2 and ethanol.
Then they were kept in the recycling loop for 30 min at
25 MPa and 333 K to ensure an effective dissolution of
the lipids and guarantee a homogeneous solution. After
that, the solution was led to the low-pressure system in
order for it to expand. According to the authors, there is
formation of foam during the expansion of the supercrit-
ical fluid in the presence of the aqueous solution. In
order to suppress the foam formation, a static mixer was
added to the recycling loop. Thereafter the expansion,
lipids were precipitated, brought in contact with the
aqueous solution, and kept in the recycling loop for
other 30 min in order to form liposomes. Liposomes
obtained by this process presented a bimodal distribu-
tion with an average size of 200 nm, and this method
used 15 times less organic solvent to get the same
encapsulation efficiency as conventional techniques.
However, the encapsulation efficiency of hydrophilic
compounds in liposomes was about 15%, which is about
50% less than the encapsulation of water-soluble com-
pounds in liposomes made by DRV or reverse-phase
evaporation methods. Due to the complexity of this
process, there are no other studies involving liposome
production by this method.Rapid expansion of supercritical solution process
Rapid expansion of supercritical solution (RESS) process
consists of the saturation of scCO2 with the solute
followed by a rapid expansion of the solution through a
heated nozzle to a low-pressure chamber. The rapid ex-
pansion/decompression is achieved by allowing passage
through a nozzle at supersonic speeds. The decrease of
the pressure forces the evaporation of CO2, leading to
the supersaturation and then precipitation of the solid
that is collected from the gaseous stream [45,46].
Table 1 Different supercritical fluid methods utilized for liposomes production
Method Phospholipid composition Active ingredient Particle size Reference
Supercritical liposome method Phosphatidylcholine, phosphatidylserine,
and cholesterol
FITC-dextran and TSZnPc ~200 nm [27]
Rapid expansion of supercritical
solution process
Phosphatidylcholine and cholesterol Atractylodes macrocephala essential oil ~173 nm [28]
Depressurization of an expanded solution
into aqueous media
Diastearoylphosphatidylcholine and cholesterol - 50 to 200 nm [29]
Solution-enhanced dispersion by supercritical
fluid process
Soy phospholipids Puerarin 1 μm [30,31]
Gas anti-solvent process Soy phospholipids - - [31]
Phosphatidylcholine and cholesterol Amphotericin B 0.5 to 3 μm [32]
Aerosol solvent extraction system Phosphatidylcholine and cholesterol Miconazole DNS [33]
Supercritical anti-solvent process Lecithins S20, S75, and S100 - 1 to 40 μm [34]
Lecithin S75 - 1 to 40 μm [35]
Lecithin S75 Fluorescent markers 0.1 to 100 μm [26]
Hydrogenated soy phosphatidylcholine,
soy phosphatidylcholine, and cholesterol
Docetaxel 200 to 300 nm [36]
Hydrogenated soy phosphatidylcholine Vitamin D3 1 μm [37]
Hydrogenated soy phosphatidylcholine Lutein 200 to 500 nm [38]
Continuous anti-solvent process Soy lecithin - 0.1 to 100 μm [39,40]
Supercritical reverse-phase evaporation Dipalmitoylphosphatidylcholine Glucose and cholesterol 0.1 to 1.2 μm [41]
Phosphatidylcholine, phosphatidylethanolamine,
phosphatidylinositol, and phosphatidic acid
Glucose and cholesterol 0.1 to 1.2 μm [42]
Phosphatidylcholine and dioleoylphosphatidylcholine Glucose 0.1 to 1.2 μm [14]
Improved supercritical reverse-phase evaporation Dipalmitoylphosphatidylcholine Glucose 1.5 μm [43,44]

















Figure 1 Schematic representation of the apparatus utilized by Frederiksen et al. [27]. Composed of a (I) CO2 pump, (II) modifier pump,
(III) high-pressure recycling pump, (IV, 4) pulse dampener capillary, (V) low-pressure recycling pump, (1) CO2 cylinder, (2) cooling device, (3, 11)
manometer, (5) waste flask, (6) measuring cylinder, (7) pump T-piece, (9) dynamic mixer, (10) filter, (12, 20, 24) T-piece, (13) cartridge guard
column, (14) UV detector, (15) Plexiglas water bath, (16) high-pressure recycling system, (17) pressuring transducer, (18) back-pressure regulator,
(19) pressure controller, (21) checking valve, (23) encapsulation capillary, (25) static mixer, (26) liposomal suspension reservoir, (27) low-pressure
recycling system, and (28) fume cupboard to remove CO2; a, b, c, d, e, f, g, h, i, k, j, l, m, n, and o are valves.
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lipid vesicles because (1) phospholipids are not completely
soluble in pure scCO2 and (2) liposomes can only be com-
pletely formed in an aqueous medium. Thus, Wen et al.
[28] developed some modifications in the conventional
RESS process to produce liposomes. The schematic repre-
sentation of the apparatus is depicted in Figure 2. Phosphat-
idylcholine, cholesterol, and the essential oil of Atractylodes
macrocephala Koidz were dissolved in a mixture of scCO2/
ethanol, and after the system reached equilibrium, a buffer
solution was injected by a syringe pump into the dissolved
solutes. The final mixture was expanded through a nozzle
into the collector to evaporate CO2. According to the au-
thors, liposomes formed by this method presented goodFigure 2 Schematic representation of the RESS apparatus used by We
are found: (1) CO2 cylinder, (2) heat exchanger, (3) refrigerating machine, (4
(9) storage tank, (10) rotameter, and (11) volumetric cylinder.physicochemical characteristics and a higher encapsulation
efficiency was obtained with pressures up to 20 MPa, tem-
peratures of 323 to 338 K, and ethanol mole fractions of 5%
to 15% in scCO2. The optimization of the method provided
liposomes with spherical morphology, narrow size distribu-
tion with an average size of 173 nm, and encapsulation
efficiency of 82.18% at 30 MPa, 338 K, and ethanol amount
of 15%.
Depressurization of an expanded solution into
aqueous media
Meure et al. [29] developed a process (depressurization
of an expanded solution into aqueous media (DESAM))
that can remove almost every organic solvent added inton et al. [28] to produce liposomes. In this apparatus, the following
, 8) syringe pump, (5) reactor, (6) coaxial injector, (7) collector,
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temperatures and pressures below 6 MPa. In this tech-
nique, a fast and simple process for bulk liposome
formation was developed. Phospholipids were initially
dissolved in organic solvents - ethanol or chloroform.
Then, CO2 was sparged into the system with a syringe
pump in order to form an expanded lipid solution inside
the expansion chamber. This expansion occurs because
the gas rapidly diffuses into the solution, promoting the
phenomenon. After that, the expanded lipid solution
was atomized through a nozzle into a heated aqueous
media. When ethanol was utilized to dissolve the lipids,
the expansion chamber parameters were 295 K and 5.0
to 5.5 MPa, while the parameters were 294 K and 3.8 to
4.0 MPa when chloroform was utilized. According to the
authors, the residual solvent concentration was less than
4% v/v in all liposome preparations. This value is less
than another supercritical method that had values of re-
sidual solvent volume fraction of 14% to 17% v/v [27].
The apparatus depicted in Figure 3 was utilized to per-
form the experiments of liposome production from 50
to 200 nm.
Solution-enhanced dispersion by supercritical fluid process
Li et al. [30,31] implemented a method of production
of phospholipid complex encapsulating puerarin utilizing
solution-enhanced dispersion by supercritical fluid (SEDS)
process in a semi-continuous operation. In SEDS process,
the supercritical fluid acts not only as an anti-solvent but
also as a dispersion medium. The solution is provided from
the outer passage and dispersed by the supercritical fluid
which is quickly introduced in the inner passage. Due to
the presence of a premixing chamber in the inner nozzle,
the solution and anti-solvent can be molecularly dispersed
before the formation of the solution jet. This contact ofFigure 3 Apparatus utilized for DESAM process developed by Meuresupercritical fluid and liquid solution streams leads to the
generation of a finely dispersed mixture followed by particle
precipitation [2,3]. Furthermore, as it is an efficient single-
step, totally enclosed, and easy-to-scale up process, it can
produce more homogeneous particles for drug delivery
systems.
So, for liposome production [30,31], phospholipid
complex is defined as the presence of active substances
inside phospholipid vesicles at solid state. The represen-
tation of the apparatus is depicted in Figure 4. Puerarin
is an isoflavone and one of the major constituents of
Pueraria lobata (Willd.) Ohwi, a plant utilized in trad-
itional medicine [47]. Organic liquid solution of puerarin
and soy phospholipids was added cocurrently with CO2
by two syringe pumps into the particle formation vessel.
CO2 and the liquid solution were sprayed into the vessel
through a coaxial nozzle. A high flow rate of CO2 was
utilized to promote mixture of the organic solution with
scCO2. Therein the organic solvents utilized are dis-
persed from the bulk of the solution, leading to the ex-
traction of the solvents and the precipitation of the
particles. A temperature range of 303 to 313 K, pressure
range of 8 to 12 MPa, CO2 flow rate of 25 to 65 mL
min−1, and proportion of the solution flow rate to scCO2
from 1% to 5% were chosen by the authors to be the op-
eration parameters, which were optimized at 308 K, 10
MPa, CO2flow rate of 45 mL min
−1, and the solution-to-
scCO2 flow rate proportion of 1%. Under this optimized
conditions, puerarin-phospholipid vesicle complex of 1
μm and agglomerates of 5.93 μm were obtained. This
process was shown to be efficient in the production of
micrometric phospholipid complexes in just one step.
However, the authors did not measure the residual
solvent concentration in the particle to ensure that the
particles were almost free of solvents.et al. [29].
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In the gas anti-solvent (GAS) process, compressed gas is
gradually introduced into a liquid solution. This ability
to solubilize large amount of gases is the basis of this
technique. This solubilization leads to a volumetric ex-
pansion of the liquid phase followed by a decrease of the
liquid solvent strength, resulting in the precipitation of
small particles of the solute. The major advantage of
GAS process is the possibility of processing a wide range
of compounds and also the possibility of controlling par-
ticle size and distribution. However, as particles are pro-
duced in a liquid medium, it requires another stage for
drying the particles [48,49].
Taking GAS process characteristics into account, Li et al.
[31] also tried to produce a phospholipid complex with
puerarin by this method. But instead of using a semi-
continuous configuration as used in SEDS process, the
plant was utilized in a batch configuration. The apparatus
utilized by the authors was the same as depicted in Figure 4
with one modification - the ethanolic or chloroformic liquid
solution was added into the particle formation vessel before
it was closed, instead of pumping the solution into the
chamber. So, one syringe pump was not used to perform
this process. After the addition of the solution, the scCO2
was pumped into the vessel and left for 3 h without agita-
tion at 10 MPa and 311 K. The flow rate of CO2 was
maintained constant during the experiment in order to re-
move the organic solvents of the solution, and the slow
depressurization of the system occurred at the same
temperature of the experiments. However, this process was
not able to produce phospholipid complexes.Figure 4 Representation of the SEDS process apparatus utilized by LiIn another study, Kadimi et al. [32] produced liposomes
at 15.0 MPa and 333 K encapsulating amphotericin B based
on the GAS process. The vesicle efficacy was tested against
Aspergillus fumigatus. Briefly, solutions of phospholipids,
chloroform, and methanol were loaded into an autoclave.
Then, CO2 was pumped till the pressure arrived 15.0 MPa
and the temperature was set at 333 K. The compressed
CO2 was released into the autoclave. After the equilibration
period, a saline solution was pumped into the autoclave to
induce the liposome formation, and then, the vessel was
slowly depressurized. Also, in order to compare the results
with different methods, liposomes were also produced by
thin-film hydration [21]. Liposomes produced by supercrit-
ical technique were smaller (0.15 to 3 μm for GAS method
against 0.15 to 6 μm by thin-film hydration), with better
morphology and size distribution than the vesicles made by
the conventional method. Also, vesicles made by the GAS
process presented better antifungal activity against the A.
fumigatus strain, with an encapsulation efficiency of 25% to
30% of amphotericin B.
Aerosol solvent extraction system
Kunastitchai et al. [33] applied aerosol solvent extraction
system (ASES) process to produce liposomes entrapping
miconazole, an imidazole antifungal agent. The produc-
tion of these liposomes was done in two steps: (1) obten-
tion of a miconazole-phospholipid complex by ASES
and (2) further hydration with aqueous phosphate buffer
in order to form the phospholipid vesicles. Different
amounts of miconazol (19% and 38%) and ratios of
phosphatidylcholine/cholesterol (8:2 and 10:0, w/w) wereet al. [31].
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(2:8 w/w) with or without the addition of poloxamer
407. These solutions were sprayed through a nozzle with
a diameter of 0.4 mm into a high-pressure vessel
filled with scCO2 to remove the organic solvents and
precipitate the dried liposomes. In order to optimize the
process of liposome formation, temperature, pressure,
and CO2 density ranges used were 308 to 328 K, 8.5 to
10.5 MPa, and 0.30 to 0.50 g mL−1, respectively. The
CO2 flow rate was 6 kg h
−1 and spraying rate was 6 mL
min−1. After the atomization, the solution was washed
with scCO2 in order to extract the remaining organic
solvents. Then, it was hydrated with phosphate buffer at
different pH levels (4.0 and 7.2) and submitted to gentle
agitation at 328 K. According to the authors, the per-
centage yield of liposome formation was higher when
the temperature used was 308 K and the CO2 density
was 0.30 g mL−1. Therefore, the optimized parameters
utilized were 308 K, 8.0 MPa, and 0.30 g mL−1.
Supercritical anti-solvent process
Supercritical anti-solvent process (SAS) is the most
popular precipitation process involving supercritical
anti-solvent due to the wide range of compounds that
can be used, the control of particle size and distribution,
and the facility of adaptation for a continuous operation
[3,50]. Basically, the compound is dissolved in a liquid
solvent and sprayed to a chamber that already has super-
critical fluid, leading to their rapid contact. This contact
causes supersaturation of the solution, then fast nucle-
ation, and consequently, diffusion of the anti-solvent in
the liquid phase and formation of small particles [51,52].
Badens et al. [34] and Magnan et al. [35] produced
liposomes from three different lecithins: S20, S75,
and S100. These lecithins contained different amounts
of phosphatidylcholine, phosphatidylethanolamine, andFigure 5 The SAS apparatus utilized for the production of liposomesphosphatidylinositol. Different operation parameters
were analyzed by this study, such as pressure (8.0 to
12.0 MPa), temperature (303 to 323 K), and liquid so-
lution flow rate (10 to 40 mL h−1). CO2 flow rate value
was maintained constant during all the experiments.
The vesicle formed had a diameter size between 1 and
40 μm, had a spherical shape, was partly agglomerated,
and seemed to be free of solvent, according to infrared
analysis. The apparatus that was used for these studies
is depicted in Figure 5.
Lesoin et al. [26] compared liposomes produced by
SAS and the thin-film hydration methods in an appar-
atus similar to the one depicted in Figure 5. According
to the authors, the vesicles produced by supercritical
fluids presented a spherical shape, bimodal size distribu-
tion in the range of 0.1 to 100 μm, and encapsulation ef-
ficiency of fluorescent markers of 20%. However, the
ellipsoidal vesicles made by the traditional method
seemed to be more dispersed, but this method has ser-
ious issues of reproducibility and repeatability, which
makes the supercritical process more attractive than the
conventional one.
Another interesting study described the production
of PEGylated liposomes using the SAS process to en-
capsulate docetaxel, one of the most important chemo-
therapeutic agents against cancer. Hydrogenated soy
phosphatidylcholine (PC), soy PC, and cholesterol in
different proportions were utilized to produce the
vesicles with DSPE-PEG2000. The utilization of satu-
rated and unsaturated phospholipids enhanced the
liposomal stability in about 3 months with high entrap-
ment efficiency. So, docetaxel and the phospholipids
were dissolved in chloroform and methanol. This solu-
tion was sprayed into a high-pressure vessel where the
operational temperature and pressure were then set.
Once the system reached the steady state, the lipid[35].
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to permit the mixing of the phases and, consequently, pre-
cipitating the lipid particles in the vessel. The vesicles
formed were small and unilamellar with a size range be-
tween 200 and 300 nm. In vitro release studies showed that
the vesicles presented controlled drug release during 48 h.
No residual organic solvent at the end of the preparation
was found. The authors concluded that PEGylated lipo-
somes produced by supercritical fluid technology are more
stable, have smaller size, and are free from residual organic
solvent [36].
Xia et al. [37,38] produced proliposomes using the
supercritical anti-solvent process. It was shown that the
proliposomes, which are dry free-flowing particles, have
a media size of 200 nm with a narrow size distribution.
The increased pressure utilized in the system (8.0 to
12.0 MPa) favors the formation of small molecules. After
the hydration, the formed liposomes encapsulating lutein
had a size of about 500 nm, while vesicles encapsulating
vitamin D3 presented 1 μm, approximately. The authors
affirm that the proliposomes are easily hydrated, produ-
cing unilamellar liposomes. The vesicles formed by
supercritical fluids have entrapping efficiency of lutein
and vitamin D3 that reaches 90% each.
Continuous anti-solvent process
Lesoin et al. [39,40] developed a new single-step super-
critical process to produce liposomes called continuousFigure 6 Schematic representation of the CAS apparatus utilized by L
(2) volumetric pump, (3) heater, (4) flow indicator transmitter, (5) temperatu
(9) stirring, (10) control valve, and (11) dryer.anti-solvent process (CAS) (Figure 6). Two different pro-
cedures were developed for this method: CAS1 and
CAS2. The difference between the processes is the num-
ber of exits: while CAS1 is a single-exit process, CAS2
has two exits. In CAS1, an initial amount of aqueous
phase was added inside the autoclave followed by the in-
jection of CO2. The organic solution was sprayed to the
autoclave while the liquid phase was under stirring.
When the phases were in equilibrium, a valve at the bot-
tom of the autoclave was opened, releasing the CO2 and
the liposome suspension. In order to maintain the same
amount of liquid inside the autoclave, an aqueous solu-
tion was injected in a continuous way. On the other
hand, in the CAS2 method, the aqueous phase was
added into the autoclave and then it was filled with CO2.
When the work pressure was reached, the organic solu-
tion was added similarly to the CAS1 method. However,
when the system seemed to be homogeneous, a valve on
the top of the autoclave was opened, releasing the CO2,
and the liposomal suspension was recovered from the
bottom of the vessel. The mean diameter of liposomes
produced by the CAS methods ranged from 0.1 to
100 μm.
Supercritical reverse-phase evaporation and improved
supercritical reverse-phase evaporation
Developed by Otake et al. [41], the supercritical reverse-
phase evaporation (scRPE) is a batch process thatesoin et al. [40]. In this apparatus, the following are found: (1) cooler,
re indicator, (6) back-pressure valve, (7) safety valve, (8) release valves,
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CO2 at a constant temperature (333 K) and pressure
(20.0 MPa) values. The temperature value has to be
higher than the lipid phase transition in order to ensure
the complete dissolution of the lipid in the supercritical
phase. Basically, CO2 was inserted into a cell with
variable volume (depicted in Figure 7) after it was
already sealed with ethanol and different amounts of
dipalmitoylphosphatidylcholine (DPPC). Then the work-
ing temperature and pressure were set and the system
was kept in equilibrium for several minutes. After that,
an aqueous glucose solution (0.2 mol L−1) was added by
an HPLC pump with a flow rate of 0.05 mL min−1. After
the solution was completely added, the system was
slowly depressurized forming liposomes with sizes from
0.1 to 1.2 μm with an encapsulation efficiency of 25% for
glucose. In addition, the encapsulation efficiency of lipo-
philic substances was also studied and cholesterol was
the model molecule utilized. For this substance, the
reached encapsulation efficiency was 63%.
In order to investigate if this method was also compat-
ible with phospholipids other than DPPC, Imura et al.
[42] prepared different soybean lecithin-based liposomes.
The lipid vesicles produced in this study were consti-
tuted of phosphatidylcholine and three different natural
lecithins, which are mixtures of PC, phosphatidyletha-
nolamine (PE), phosphatidylinositol (PI), and phospha-
tidic acid (PA) in different concentrations. Pressure and
temperature values were the same as those used by
Otake et al. [41]. It was shown that liposomes from dif-
ferent lecithins can be formed, and as expected, their
size and shape were dependent on the solubility of the
lipid in the supercritical phase. Liposomes constitutedFigure 7 Schematic representation of the scRPE apparatus.by PC presented size diameter varying from 0.2 to 1.2
μm and spherical shape, while vesicles formed by a nat-
ural lecithin (32% PC, 31% PE, 17% PI, and 9% PA) were
ellipsoidal vesicles with diameter of 0.1 to 0.25 μm.
Based on these previous results, Imura et al. [14] decided
to improve the encapsulation efficiency of glucose and the
stability of the vesicles adding a different phospholipid to
the composition, the dioleoylphosphatidylcholine (DOPC).
So, liposomes formed by DOPC or DPPC were prepared
with pressures between 130 and 30.0 MPa and temperature
of 333 K. It was shown that the maximum glucose-
entrapping efficiency for liposomes made of DOPC was
40% (20.0 MPa and 333 K) and 20% for DPPC at the same
conditions. It can be noticed that the enhancement of en-
trapping efficiency was not too significative if this study is
compared with other studies of the group [41].
Otake et al. [43,44] simplified the scRPE method in
order to enhance the liposome entrapment efficiency.
The lipid vesicles were still produced inside a view cell
with variable volume; however, the organic solvent was
excluded of the mixture, generating an inhomogeneous
mixture of phospholipids and aqueous solution at the
same parameters utilized for the scRPE method. The
system was submitted to magnetic stirring and then
pressurized. After the equilibrium period of 40 min, ap-
proximately, the system was depressurized and lipo-
somes with mean diameter of 1.5 μm were formed.
Solid lipid nanoparticles
Created in the 1990s, solid lipid nanoparticles (SLNs)
are colloidal particles composed of lipids which are
solids in ambient temperature. The term lipid includes
triglycerides, partial glycerides, fatty acids, steroids, and
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prolonged profile; thus, after administration, a constant
concentration of the drug molecule can be maintained
in the blood stream. The maintenance of constant
plasma levels implies possible reduction of side effects
and reduces the frequency of doses of pharmaceuticals.
The literature has demonstrated that beyond the com-
position of lipid matrix, the method of preparation
seems to have an important role in the definition of the
release mechanism of drug molecule [53-56].
Currently a wide range of techniques for the produc-
tion of SLN is available. Solvent emulsification/evapor-
ation, high-pressure homogenization, and hot and cold
homogenization have been the most cited. The choice
of these processes is favored by their feasibility for
scaling up to industry production and relatively low
overall costs of operation. On the other hand, these
traditional methods are multi-step and generally in-
volve high temperature and shear rates, and several
cycles at high pressure. These extreme process condi-
tions lead to an increase and heterogeneity of particle
size and degradation of the drug. Further, the high kin-






Supercritical fluid extraction of
emulsions








Glycerylmonostearate and Cutina® HR
Precirol® ATO 5 and/or Gelucire® 50/13
Glycerylmonostearate and Cutina® HR
Precirol® ATO 5
Myristic acid or tripalmitin
Beeswax
Ceramide 3A, cholesterol, and Radiacid®
Tristearin and Epikuron 200®
Tristearin and Epikuron 200® or tristearin,
Epikuron 200, and PEG
Tristearin, Epikuron 200®, and oleic acid
Tristearin and Epikuron 200®
NM, not measured.their coalescence and the presence of organic solvent
residues compromises their safety for human use [57].
Solid lipid particle production by scCO2 processing
Considering the broad context on manufacturing limita-
tions of SLN, the supercritical fluid technology appears
as a great opportunity to overcome them. Indeed, in this
innovative field, the obtention of solid lipid particles at
nanometer scale has been a challenging task. Even so,
the versatility of supercritical fluid-based plants often of-
fers different solutions for this issue. Table 2 summarizes
the different methods applied in the production of solid
lipid particles with diversified composition.
Supercritical fluid-based coating technique
Benoit et al. [73] developed a relatively rapid, simple, and
totally solvent-free technique for coating drug particles with
solid lipid compounds. The same group demonstrated the
performance of its proposed method by encapsulation of
bovine serum albumin (BSA) crystals with trimyristin and
Gelucire® 50/02, a commercial mixture of glycerides and
fatty acid esters [58]. The scheme of the apparatus used is
depicted in Figure 8. The mechanism of coated particlecles by supercritical fluid technology
Active ingredient Particle size Ref
Bovine serum albumin 125 to 500 μm [58]
Bovine serum albumin ~50 μm [58]
Indomethacin or ketoprofen ~30 nm [59]
Pseudoephedrine chlorhydrate or bovine
serum albumin
~60 μm [60]
Theophylline ~3 μm [61]
Caffeine ~5 μm [62]
Caffeine, glutathione, or ketoprofen NM [63]
Trans-chalcone 1 to 6 μm [64]
Ketoprofen NM [65]
Ascorbic acid ~2 μm
Ibuprofen 2 to 4 μm [66]
Menthol ~2 to 50 μm [67]
- 200 to 500 nm [68]
Insulin or recombinant human growth
hormone
~197 nm [69]
Insulin 80 to 120 nm [70]
Magnetite nanoparticles 200 to 800 nm [71]
Ribonuclease A functionalized or not with
PEG5000
4 to 13 μm [72]
Figure 8 Schematic representation of the coating process developed by Ribeiro dos Santos et al. [58]. (A) Filling step: BSA crystals (white)
and lipid material (black). (B) Solubilization of lipid in scCO2 with dispersion of insoluble BSA crystals. (C) Decompression phase with lipid
deposition on BSA. (D) Coated particles are obtained.
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solid lipid into scCO2 in a thermostatized high-pressure
mixing chamber loaded with BSA crystals. After 1 h of
mixing, the chamber was depressurized with passage of
scCO2 to gas state with consequent precipitation of the
lipid on the crystal surfaces. This work was described with
more details in three other articles [74-76]. As Gelucire is a
mixture, it does not crystallize, allowing a uniform coating
of BSA, while trimyristin crystallizes and forms a needle-
like structure around BSA crystals leading to a burst release
from the particles. However, this method is restricted to
lipids with considerable solubility into scCO2, and the par-
ticle size is dependent on the size of the original BSA crys-
tals. Thus, to obtain solid lipid particles with a narrow
range of size distribution, the bulk drug has to be processed
by an additional technique increasing the final cost of the
whole process.Figure 9 Extraction system used in the SFEE process developed by ChSupercritical fluid extraction of emulsions
The super critical fluid extraction of emulsion (SFEE)
technique, developed by Chattopadhyay and co-workers
[77], is composed of coupling of a conventional method
for oil-in-water (o/w) emulsion obtention and subse-
quent extraction process by scCO2. The emulsion is typ-
ically prepared by dissolution of a solid lipid and the
drug into an organic solvent. This organic solvent is dis-
persed into the aqueous phase by a homogenizer, using a
certain surfactant for stabilization. Then, the emulsion is
bombed until atomization through a nozzle and submit-
ted to an extraction of the organic solvent by scCO2 in
countercurrent flux with consequent solidification of
lipid droplets and collection of aqueous suspension of
solid lipid particles [77,78].
Compared to traditional methods, this technique
brings the advantage of improving the removal of theattopadhyay et al. [59].
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stability, with shorter processing time and innocuous re-
sidual solvent concentration in the final product. Fur-
thermore, due to diffusivity features of scCO2, the mass
transfer on solvent removal is more efficient in compari-
son to conventional methods, which lead to a more con-
sistent particle size distribution, avoiding aggregation.
Taking into account the smaller droplet size in the pri-
mary emulsion, smaller SLNs are obtained; the produc-
tion of the emulsion represents a pivotal step for
achievement of SLN with narrow size range [79-81].
Figure 9 describes the extraction plant used by
Chattopadhyay et al. [59] for production of SLN consti-
tuted of tripalmitin, tristearin, or Gelucire 50/13. After
preparation of an o/w emulsion with oil phase composed
of the drug and lipid dissolved in chloroform, the solvent
was extracted with scCO2 countercurrently at a flow rate
of 40 g min−1. SLNs with a mean diameter of 30 nm
were obtained, however, with a bimodal population com-
posed of a primary peak ranging from 20 to 60 nm and
a secondary peak (<10%) of about 200 nm. A residual
chloroform concentration of <20 ppm was detected that
is in accordance with the International Conference on
Harmonization guidelines whose limit for this solvent is
60 ppm [82].
Earlier, by using the SFEE plant already cited above
(Figure 8), Shekunov et al. [81] performed micronization
studies on cholesterol acetate and griseofulvin and evalu-
ated possible important factors for definition of particle
size that can be taken in consideration for SLN produc-
tion. It was observed that the droplet size, drug concen-
tration, and solvent content are the major factors with
significant influence on particle size. Naturally, when the
size of o/w emulsion droplets is smaller, smaller particles
can be obtained. Thus, the stabilization of the emulsion
by a surfactant is highly important owing to its capabilityFigure 10 The supercritical co-injection process. (Left) Schematic repre
(2) cooler, (3) pump, (4) heater, (5) saturation vessel, (6) high-pressure vesse
solid separation filter, (PI) pressure indicator, (PIC) pressure indicator and co
(Right) The co-injection device [60].to guarantee the maintenance of small droplets and
avoidance of aggregation events [83]. On the other hand,
the partial interaction of the drug molecule with the
aqueous media may promote the interaction among
droplets that aggregate and form larger particles. In
addition, considering that supersaturation in emulsion
droplets is important for the formation of small parti-
cles, the increase of solvent content promotes increase
in growth rate. These conclusions also correlate with
studies conducted with PLGA nanoparticles [84].
Supercritical co-injection process
Developed by Calderone and colleagues [85], the co-
injection process was presented as a new way for the ob-
tention of solid lipid microparticles. As described in
Figure 10, firstly, a solid lipid is melted under its normal
melting point due to the plasticizing effect exercised by
solubilization of a pressurized gas. Second, the expan-
sion of the gas-saturated melted lipid phase causes its
pulverization. This pulverization occurs in a custom-
designed co-injection device, where particles of uncoated
drug are conveyed by a Venturi system at the same time.
The co-injection provides the coating of the drug
particles [60].
This method presents the advantage of maintaining
the active component in a different reservoir than that
used for the coating material; thus, the drug component
may be exposed to ambient temperature conditions
which prevent its degradation. By using Precirol® ATO5
for coating of pseudoephedrine chlorhydrate (PSE) and
BSA, the method was tested by Calderone et al. [60].
The effective coating of the particles, with significant
retarding of drug release in aqueous media, was demon-
strated. Meanwhile, the observed drug release cannot be
classified as prolonged because of the relatively short
time for release of 100% of the entrapped PSE (50 min)sentation of the supercritical co-injection process: (1) CO2cylinder,
l, (7) valve, (8) pneumatic conveying, (9) co-injection advice, (10) gas/
ntroller, (TIC) temperature indicator and controller, and (VENT) Venturi.
Figure 11 Example of PGSS plant for particle formation for drug-loaded particles [46].
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beads for validation of this method, it was found that ag-
gregation events of beads smaller than 20 μm were very
common. It brings an important limitation on achieving
particles in nanometer scale.
Particles from gas-saturated solutions
Among the available techniques for SLN production by
supercritical fluid processing, particles from gas-saturated
solutions (PGSS) have been shown as the most interesting.
Also known as supercritical melt micronization process
[86], PGSS is a completely solvent-free process where a
solid is melted in a highly pressurized vessel pressurized by
a compressed gas. Figure 11 demonstrates a generic scheme
of a PGSS plant used for drug-loaded polymeric and lipid
particles. There, gas-saturated solution is expanded through
a nozzle, and due to the Joule-Thompson effect, it is rapidly
cooled down leading to formation of SLN [87,88]. In
addition to all advantages of supercritical fluid technology,
PGSS can produce directly powdered formulations, re-
quires the use of small-volume pressurized equipment, de-
mands relatively low amounts of CO2, easily performs
the recovery of the product and the gas, and is useful for
the production of polymer powder or the entrapping of ac-
tive ingredients in polymer matrices. This process already
runs in plants with the capacity of some hundred kilograms
per hour [89,90]. Another great advantage of the PGSS
technique resides in the plasticizing effect of scCO2 when
diffused into a polymer or lipid matrix which allows their
melting under mild temperatures, becoming feasible for
drug processing [91]. Further, PGSS usually provides
particles (μm or nm) with uniform narrow size range of
particular interest [4].
However, the mechanisms of particle formation are
not completely understood. Several studies have beenconducted for modeling of particle formation in PGSS,
and it was found that the expansion process is composed
of atomization and nucleation/crystallization phenomena
[92,93]. Briefly, atomization can be defined as the dis-
ruption of a liquid jet in fine particles during expan-
sion [94]. Further, nucleation describes the formation of
CO2 bubbles inside the fresh droplets of a mixture of
molten lipid and drug due to transition to gaseous state
of the supercritical fluid in the expansion unit, and
crystallization involves the solidification of the particle
surface and subsequent inner lipid matrix under
decrease of temperature due to the Joule-Thompson
effect [95].
Studies have demonstrated that nozzle diameter, pre-
expansion pressure and temperature, and flow rate of
carbon dioxide represent four of the most important fac-
tors for defining the size, shape, and physical state of the
particles [96]. It has been found that when the saturation
pressure is larger, a larger carbon dioxide diffusion into
polymer or lipid matrix is achieved, while there is an in-
verse relationship between scCO2solubilization and sat-
uration temperature [97]. The high content of scCO2
favored by high saturation pressure makes the nucle-
ation process occur faster than crystallization of surface
during the expansion step, leading to formation of small
particles. However, the higher the scCO2 content is, the
more violent is the disruption of the lipid matrix with
potential formation of shapeless particles. This is not a
desirable effect considering that irregularly shaped parti-
cles commonly present a burst release of the active com-
pound [95].
In the case of temperature, the opposite effect on par-
ticle size is observed, i.e., the particle size increases with
increasing temperature above the melting point of the
carrier material. This can be explained by the decrease
Figure 12 Different results obtained under different operation conditions in a PGSS method for production of PEG-600 particles.
Adapted from Kappler et al. [95].
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with lower fluid content in the particles, the crystallization
of the particle surface occurs faster than CO2 bubble for-
mation which leads to retention of the gas and less disrup-
tion events resulting in obtention of larger particles. This
phenomenon is readily observed when the selected satur-
ation temperature is already below the lipid or polymer
melting point [98]. Figure 12 presents a scheme with differ-
ent particles obtained with different operation conditions in
a work performed by Kappler and colleagues [95].
Seeing the wide range of available lipids and drug mol-
ecules, the operation conditions are unique depending
upon the specific system. Rodrigues et al. [61] producedFigure 13 Schematic of the modified PGSS apparatus adapted from V
U, nozzle; CE, expansion chamber; F, filter; R1 to R4, electric resistances; SC,
on-off valves; PR, pressure reducer; C, air compressor; D, synthetic air or nitrmicrocomposite lipid particles composed of hydroge-
nated palm oil entrapping theophylline by PGSS. Solid
lipid particles of about 3 μm were obtained by selecting
the conditions of 333 K and a range of 12 to 18 MPa for
the mixing step and a nozzle diameter of 25 μm. His
group observed that increase of pre-expansion pressure
leads to formation of more spherical and larger particles.
On the other hand, burst release of theophylline from
the particles was detected.
In a similar PGSS plant and with the same pre-
expansion operation conditions, Wang et al. [99]
achieved trimyristin and tripalmitin particles of about 2
μm loaded with ibuprofen. However, a 100-μm-diameterezzù et al. [71]. MO, electric motor; AM, stirrer; MC, mixing chamber;
heater exchanger; P1, pump; P2, manual syringe pump; V1 to V6,
ogen cylinder; TIC, temperature indicator and controller.
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uration time also have a significant role in particle size
definition. Equipped with an 80-μm-diameter nozzle and
under the same pre-expansion conditions, the same au-
thors showed less attractive results from lipid particles
synthesized with beeswax and menthol. A multimodal
population of particles ranging from 45 to 180 μm was
obtained [100]. By application of similar conditions,
Sampaio de Sousa and colleagues [62] achieved glyceryl
monostearate microparticles of about 5 μm loaded with
caffeine, though, owing to the hydrophilicity of caffeine,
it was necessary to use water as co-solvent. Further
studies on the formulation under 13 MPa and 345 K
with the addition of Cutina® HR and titanium dioxide, an
anticaking additive, showed that the low affinity of
hydrophilic compounds such as caffeine and glutathione
resulted in a low payload and a burst release. Otherwise,
a lipophilic compound, ketoprofen, presented a high en-
trapment rate and sustained release (t2h = 20%) [63].
Intending the successful achievement of solid lipid
particles in nanometer scale, Bertucco et al. [101] devel-
oped a modified PGSS method in which the particle for-
mation is assisted by an auxiliary gas, synthetic air,
nitrogen, or the combination of both, as depicted in
Figure 13. This modification enabled the obtention of
submicron-sized lipid particles. Based on this method, at
pre-expansion conditions set at 15.0 MPa and 313 K and
a 100-μm nozzle, SLNs loaded with insulin or human
growth hormone (HGH) were produced with a lipid
matrix composed of phosphatidylcholine and tristearin,
spherical shape, a mean diameter of 197 nm, and a mean
loading efficiency of 57% and 48% for insulin and HGH,
respectively [69]. Taking into account the hydrophilic
nature of some bioactive compounds like insulin, HGH
and other proteins, dimethyl sulfoxide (DMSO) is com-
monly used to facilitate their homogeneous dispersion in
the lipid mixture [69,70,72]. The addition of DMSO in
the formulation promoted an increase in loading effi-
ciency to 80%, with values of residual solvent below 20
ppm [70]. By using of the same saturation conditions,
SLNs based on tristearin and magnetite nanoparticles
(Fe3O4) of about 200 nm were also produced, and the
loading capacity was slightly increased with the addition
of phosphatidylcholine [71].
The good results obtained by Bertucco and col-
leagues in entrapping hydrophilic compounds in SLN,
with maintaining of a sustained release, reveal the ne-
cessity of selecting the correct emulsifier and/or co-
solvent. Without them, not only a low encapsulation
rate is achieved, but during particle formation in the
expansion unit, a phase separation between the drug
and the lipid may occur. This condition favors the de-
position of the drug on the particle surface generating
a burst release [63].Conclusions
A large number of supercritical fluid processes for the
production of different drug delivery systems were
found in the literature, which can demonstrate that
this technology is suitable for the design of lipid
micro- and nanoparticles, namely liposomes and solid
lipid nanoparticles. Furthermore, it can be seen that
the use of supercritical fluid-based processes enables
more homogenized particles and reduces the environ-
mental impact. Despite the promising features of these
techniques, the scalability outside scientific laborator-
ies and industrial implementation of these processes
are still expensive, limiting the industrial production of
these particles using these fluids.
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